SCHEMBL1948769

SCHEMBL1948769

CCN1Cc2c(cccc2[N+](=O)[O-])C1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 2/20 0.42
HTT P42858 4/20 0.42
MAPT P10636 5/20 0.42
KMT2A Q03164 3/20 0.42
RECQL P46063 2/20 0.42
MCL1 Q07820 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 4/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
HSP90AA1 P07900 2/20 0.40
MAPK1 P28482 2/20 0.40
LMNA P02545 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ATM Q13315 1/20 0.40
IDH1 O75874 1/20 0.40
TDP1 Q9NUW8 2/20 0.40
PTPRC P08575 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9933768 0.82 IDH1 (0.45) S100A4HTTMAPTKMT2ARECQL
SCHEMBL7950879 0.82 ALDH1A1 (0.42) S100A4HTTMAPTKMT2ARECQL
SCHEMBL14348206 0.82 DHPS (0.54) HTTMAPTKMT2ARECQLMCL1
SCHEMBL31598720 0.80 S100A4 (0.46) S100A4HTTMAPTKMT2ARECQL
SCHEMBL5906644 0.80 S100A4 (0.46) S100A4HTTMAPTKMT2ARECQL
SCHEMBL16269233 0.80 ACHE (0.38) HTTMAPTKMT2ARECQLMCL1
SCHEMBL30908473 0.79 IDH1 (0.48) MAPTKMT2AMEN1NPC1RAB9A
SCHEMBL19582373 0.78 CYP1A2 (0.43) S100A4HTTMAPTKMT2ARECQL
SCHEMBL3594499 0.77 ACE (0.40) HTTMAPTALDH1A1NPC1RAB9A
SCHEMBL30450709 0.77 KMT2A (0.47) S100A4HTTMAPTKMT2ARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2438044-B1 COMPOUNDS JAPAN TOBACCO INC (JP) 2019-01-23 EP disclosed
US-8399481-B2 Compounds XENTION LTD (GB) 2013-03-19 US disclosed
US-20120157494-A1 ISOINDOLYL COMPOUNDS HARRIS III RALPH NEW (US) 2012-06-21 US disclosed
EP-2438044-A1 COMPOUNDS Xention Limited (GB) 2012-04-11 EP disclosed
US-20110136859-A1 Compounds XENTION LTD. (GB) 2011-06-09 US disclosed
WO-2010139953-A1 COMPOUNDS XENTION LIMITED (GB) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136859-A1 Compounds CYP2C8, CYP3A7, CYP2A7 S100A4 4591/4885HTT 3400/4885MAPT 4581/4885
US-20120157494-A1 ISOINDOLYL COMPOUNDS P2RX7, P2RX3, P2RX1 S100A4 1340/4885HTT 2112/4885MAPT 3117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.